NeuroMab™ Anti-CD20 BBB Shuttle Antibody(NRZP-1022-ZP3884)

Figure 1 CDC of wild-type and E345R mutants of CD20 antibody HuMAb 7D8 in competition experiments with Fc-binding peptides.

Figure 2 CDC mediated by 7D8 variants on CD20-positive Raji cells.

Figure 3 CDC mediated by 7D8 mutants (7D8-WT, K439E, S440K, K439E/S440K double mutant, K439E+S440K mixed) on CD20-positive Daudi cells.

Figure 4 Plasma concentrations of wild-type IgG1-7D8 and -E354R, -S440K and K322A variants after intravenous injection in SCID mice.

Figure 5 CDC on CD20 and CD38 positive Wien133 cells.

Figure 6A Evaluation of the in vivo efficacy of IgGl-7D8-E345R in a subcutaneous xenograft model using Raji-luc #2D1 cells.

Figure 6B Evaluation of the in vivo efficacy of IgGl-7D8-E345R in a subcutaneous xenograft model using Raji-luc #2D1 cells.

Figure 7 CDC Kinetics. Introduction of the E345R mutation in the bispecific antibody CD38×EGFR, which monovalently binds EGFR-negative Raji cells, resulted in more rapid and massive CDC-mediated lysis of target cells.

Figure 8A CDC of CD20-positive, CD38-negative Wienl33 cells or Raji cells by CD20/CD38 bispecific antibodies with and without the E345R mutation.

Figure 8B CDC on CD20 positive, CD38 negative Wienl33 cells or Raji cells by CD20/CD38 bispecific antibody with and without E345R mutation.

Figure 9 CDC of CD38-positive, EGFR-negative Wien133 cells by CD38/EGFR bispecific antibody with E345R mutation.

Figure 12A Binding of wild-type IgG1-7D8 and mutant IgG1-7D8-E345R to human FcRn as determined by ELISA at pH 6.

Figure 12B Binding of wild-type IgG1-7D8 and mutant IgG1-7D8-E345R to cynomolgus FcRn as determined by ELISA at pH 6.

Figure 12C Binding of wild-type IgG1-7D8 and mutant IgG1-7D8-E345R to mouse FcRn as determined by ELISA at pH 6.